Tubeimoside I

Tubeimoside I is an orally active HSPD1 inhibitor. Tubeimoside I inhibits NF-κB, MAPK, as well as regulates eNOS-VEGF. Tubeimoside I induces cytoprotective Autophagy via an Akt-mediated pathway. Tubeimoside I inhibits proinflammatory cytokine (IL-6 and IL-1β) production. Tubeimoside I exhibits anti-inflammatory activities. Tubeimoside I promotes angiogenesis and improves sepsis symptoms. Tubeimoside I is used in the research of inflammatory diseases, various cancers, sepsis and ischemic diseases[1][2][3][4][5][6][7][8][9][10][11].

Product Specifications

CAS Number

[102040-03-9]

Product Name Alternative

Tubeimoside-1; Lobatoside-H

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Akt; Autophagy; HSP; Interleukin Related; NF-κB; p38 MAPK; VEGFR

Type

Natural Products

Related Pathways

Autophagy; Cell Cycle/DNA Damage; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Tubeimoside-I.html

Concentration

10mM

Purity

99.96

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

C[C@@]12C([C@@]3([H])[C@](C(O[C@@H]4OC[C@H](O)[C@H](O)[C@H]4O[C@@H]5O[C@@H](C)[C@H](OC(C[C@](O)(C)CC6=O)=O)[C@@H](O[C@@H]7OC[C@@H](O)[C@H](O)[C@H]7O)[C@H]5O)=O)(CCC(C)(C)C3)CC2)=CC[C@@]8([H])[C@@]1(C)CC[C@]([C@](C)(CO)[C@H]9O[C@@H]%10O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%10O[C@@H]%11OC[C@H](O6)[C@H](O)[C@H]%11O)([H])[C@]8(C)C[C@@H]9O

Molecular Formula

C63H98O29

Molecular Weight

1319.43

Precautions

H302, H315, H319, H335

References & Citations

[1]Jiang SL, et al. Tubeimoside-1, a triterpenoid saponin, induces cytoprotective autophagy in human breast cancer cells in vitro via Akt-mediated pathway. Acta Pharmacol Sin. 2019 Jul;40 (7) :919-928.|[2]Wang K, et al. Tubeimoside I-induced lung cancer cell death and the underlying crosstalk between lysosomes and mitochondria. Cell Death Dis. 2020 Aug 26;11 (8) :708.|[3]Feng X, et al. Tubeimoside I induces accumulation of impaired autophagolysosome against cervical cancer cells by both initiating autophagy and inhibiting lysosomal function. Cell Death Dis. 2018 Nov 2;9 (11) :1117.|[4]Xu Y, et al. Multiple pathways were involved in tubeimoside-1-induced cytotoxicity of HeLa cells. J Proteomics. 2011 Dec 21;75 (2) :491-501. |[5]Yang JB, et al. Tubeimoside-1 induces oxidative stress-mediated apoptosis and G0/G1 phase arrest in human prostate carcinoma cells in vitro. Acta Pharmacol Sin. 2016 Jul;37 (7) :950-62.|[6]Wang Y, et al. Natural plant extract tubeimoside I promotes apoptosis-mediated cell death in cultured human hepatoma (HepG2) cells. Biol Pharm Bull. 2011;34 (6) :831-8.|[7]Wu Q, et al. Tubeimoside-1 attenuates LPS-induced inflammation in RAW 264.7 macrophages and mouse models. Immunopharmacol Immunotoxicol. 2013 Aug;35 (4) :514-23. |[8]Zhang JB, et al. Tubeimoside I attenuates inflammation and oxidative damage in a mice model of PM2.5-induced pulmonary injury. Exp Ther Med. 2018 Feb;15 (2) :1602-1607. |[9]Luo M, et al.Tubeimoside I improves survival of mice in sepsis by inhibiting inducible nitric oxide synthase expression. Biomed Pharmacother. 2020 Jun;126:110083.|[10]Wu T, et al. Tubeimoside-I, an inhibitor of HSPD1, enhances cytotoxicity of oxaliplatin by activating ER stress and MAPK signaling pathways in colorectal cancer. J Ethnopharmacol. 2025 Jan 10;336:118754. |[11]Yang X, et al. Tubeimoside I promotes angiogenesis via activation of eNOS-VEGF signaling pathway. J Ethnopharmacol. 2021 Mar 1;267:113642.